• Tue, June 28, 2022
Roy Buchanan Maintained (ABUS) at Buy with Decreased Target to $9 on, Jun 28th, 2022
Roy Buchanan of JMP Securities, Maintained "Arbutus Biopharma Corporation" (ABUS) at Buy with Decreased Target from $10 to $9 on, Jun 28th, 2022.
Roy has made no other calls on ABUS in the last 4 months.
There are 2 other peers that have a rating on ABUS. Out of the 2 peers that are also analyzing ABUS, 0 agree with Roy's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Roy
- Ed Arce of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $8.5 on, Monday, March 14th, 2022
- Keay Nakae of "Chardan Capital" Maintained at Strong Buy with Increased Target to $6 on, Friday, March 4th, 2022
Like: 👍
